News & Presentations

Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation, a Novel Approach for the Differentiation and Expansion of Induced Pluripotent Stem Cells to Generate Cytotoxic Innate Lymphocytes
July 28, 2022

New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™) as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACR™ synthetic cytokine receptor system Umoja’s RACR-driven ShRED platform addresses multiple iPSC-derived immune cell manufacturing…

READ MORE >

Umoja Biopharma Announces Participation in Upcoming Scientific Summits
June 30, 2022

SEATTLE, June 30, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.

READ MORE >

Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting
June 16, 2022

SEATTLE, June 16, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have a poster presentation at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, to be held June 15-18, 2022 in San Francisco, California.

READ MORE >

Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology
June 10, 2022

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France, June 10, 2022 – Umoja Biopharma, Inc.,…

READ MORE >

Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
May 23, 2022

SEATTLE and DALLAS, May 23, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, and Lupagen, Inc., a gene therapy company developing first-in-class gene delivery technologies for CAR-T, gene editing and immunotherapy products, today announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.